Ritlecitinib CAS 1792180-81-4 Pharmaceutical Grade Raw Ritlecitinib
TDS 5 Inquiries
1792180-81-4
Pharmaceutical Grade
99%
shenzhen
HS
25kg drum
Yes
2026-04-24
Ivermectin,Active pharmaceutical ingredients,Cosmetics material,Chemical intermediate,Nootropic,Food additive
-
Product Details
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferencePF-06651600 is under investigation in clinical trial NCT02974868 (Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata).|Ritlecitinib is an orally available small-molecule inhibitor of tyrosine-protein kinase JAK3 (Janus kinase 3; JAK3) with potential immunomodulatory and anti-inflammatory activities. Upon administration, ritlecitinib selectively and irreversibly binds to JAK3 and prevents the activation of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This may decrease the production of certain pro-inflammatory cytokines and prevent both an inflammatory response and the inflammation-induced damage caused by certain immunological diseases. By selectively targeting JAK3, PF-06651600 may spare interleukin (IL)-6 signaling, as well as other JAK1-dependent immunoregulatory cytokines such as IL-10, IL-27, and IL-35, which may offer a safety benefit compared to non-selective JAK inhibitors. JAK kinases are intracellular enzymes involved in signaling pathways affecting hematopoiesis, immunity and inflammation.
Ritlecitinib, a dual JAK3/TEC inhibitor, was granted FDA breakthrough status for treating alopecia areata (autoimmune-induced hair loss) in September 2018. Promising phase 3 trial results in alopecia areata were reported by Pfizer in August 2021, placing it in competition with Lilly/Incyte’s Olumiant. It is also used in clinical studies to treat vitiligo, rheumatoid arthritis, Crohn’s disease, and ulcerative colitis. Ritlecitinib achieved high JAK3 selectivity via covalent interaction with a unique cysteine residue (Cys909) in the catalytic domain.CertificatesBasic Info-
Product Name:
Ritlecitinib
Other Name:1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one;1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2;PF-06651600;PF 06651600;PF06651600;1-[(2S,5R)-2-methyl-5(7H-pyrrolo[2,3-d]pyrimidine-4-ylamino)-1-piperidinly]-2-propen-1-one malonate,PF06651600;Ritlecitinib;2-Propen-1-one, 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-;1-[(2S,5R)-2-Methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one;Ritlecitinib (PF-06651600)
CAS No.:1792180-81-4
Molecular Formula:C15H19N5O
InChIKeys:CBRJPFGIXUFMTM-WDEREUQCSA-N
Molecular Weight:285.34
Exact Mass:285.15896025
EC Number:210-077-2
UNII:2OYE00PC25
NCI Thesaurus Code:C161783
Color/Form:white to beige
Categories:
Characteristics-
Density:
1.272±0.06 g/cm3(Predicted)
Water Solubility:H2O: 5mg/mL, clear (warmed)
PKA:13.03±0.50(Predicted)
Critical Temperature & Pressure:room temp
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Ivermectin,Active pharmaceutical ingredients,Cosmetics material,Chemical intermediate,Nootropic,Food additive
-
Location:
6 floor Baoyilongji Building B Weiyang Area, Fengcheng 8 Road, Xi'an city, Shaanxi, 710000, China
-
Payment Terms:
L/C,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
7 days
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
51-100
-
Year of Establishment:
2017
Company Certificates-
ISO
-
ISO
-
-
Inquiry History5 Inquiries
Country Product Purchase Quantity Date Posted
Pakistan
RITLECITINIB
1 MT Aug 10, 2026
Canada
Ritlecitinib
100 G Nov 28, 2025
India
RITLECITINIB
25.00 G Jul 1, 2025
United States
Ritlecitinib
1 MG Jun 6, 2025
India
RITLECITINIB
25.00 G May 7, 2025 Post an enquiry for this product
More from this Seller
-
-
-
28319-77-9 99% Alpha-GPC Choline Alfoscerate Stock Choline Glycerophosphate FACTORY PRICE
Pharmaceutical Grade / 99%
-
-
-
-
Nootropic 4-Dimethylamino 7, 8-Dihydroxyflavone CAS 1205548-00-0 4-DMA-7, 8-Dhf Hbr Powder
Pharmaceutical Grade / 99%
-
-
-
-
Food Additives Sorbitol Powder CAS 50-70-4 Sorbitol
Pharmaceutical Grade / 99%
-
-
-
-
ISO high pure 99% Ketotifen fumarate powder CAS 34580-14-8 Pharmaceutical Raw material
Pharmaceutical Grade / 99%
-


